Intrathecal onasemnogene abeparvovec for treatment-experienced patients with spinal muscular atrophy: a phase 3b, open-label trial

Journal:
Nature Medicine
Published:
Affiliations:
20
Authors:
18
Institutions Authors Share
Boston Children's Hospital (BCH), United States of America (USA)
2.000000
0.11
Novartis Pharmaceuticals Corporation, United States of America (USA)
2.000000
0.11
American Family Children’s Hospital, United States of America (USA)
1.000000
0.06
Vall d'Hebron University Hospital (HUVH), ICS, Spain
1.000000
0.06
Hôpital Femme Mère Enfant (HFME), HCL, France
1.000000
0.06
Kurume University, Japan
1.000000
0.06
Tokyo Women's Medical University (TWMU), Japan
1.000000
0.06
Children's Hospital, CHU-Toulouse, France
1.000000
0.06
Children's Hospital of The King's Daughters (CHKD), United States of America (USA)
1.000000
0.06
Novartis Pharmaceuticals UK Ltd, United Kingdom (UK)
1.000000
0.06
Novartis, Switzerland
1.000000
0.06
University Medical Center Utrecht (UMC Utrecht), Netherlands
1.000000
0.06
University Hospitals Leuven (UZ Leuven), Belgium
0.500000
0.03
Catholic University of Leuven (KU Leuven), Belgium
0.500000
0.03
The Royal Children's Hospital Melbourne (RCH), Australia
0.500000
0.03
Murdoch Children's Research Institute (MCRI), Australia
0.500000
0.03
Catholic University of the Sacred Heart (UCSC), Italy
0.500000
0.03
Agostino Gemelli University Polyclinic, Italy
0.500000
0.03
McGill University, Canada
0.500000
0.03
McGill University Health Centre (MUHC), Canada
0.500000
0.03